Cargando…
Analysis of growth factor signaling in genetically diverse breast cancer lines
BACKGROUND: Soluble growth factors present in the microenvironment play a major role in tumor development, invasion, metastasis, and responsiveness to targeted therapies. While the biochemistry of growth factor-dependent signal transduction has been studied extensively in individual cell types, rela...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234128/ https://www.ncbi.nlm.nih.gov/pubmed/24655548 http://dx.doi.org/10.1186/1741-7007-12-20 |
_version_ | 1782344800680280064 |
---|---|
author | Niepel, Mario Hafner, Marc Pace, Emily A Chung, Mirra Chai, Diana H Zhou, Lili Muhlich, Jeremy L Schoeberl, Birgit Sorger, Peter K |
author_facet | Niepel, Mario Hafner, Marc Pace, Emily A Chung, Mirra Chai, Diana H Zhou, Lili Muhlich, Jeremy L Schoeberl, Birgit Sorger, Peter K |
author_sort | Niepel, Mario |
collection | PubMed |
description | BACKGROUND: Soluble growth factors present in the microenvironment play a major role in tumor development, invasion, metastasis, and responsiveness to targeted therapies. While the biochemistry of growth factor-dependent signal transduction has been studied extensively in individual cell types, relatively little systematic data are available across genetically diverse cell lines. RESULTS: We describe a quantitative and comparative dataset focused on immediate-early signaling that regulates the AKT (AKT1/2/3) and ERK (MAPK1/3) pathways in a canonical panel of well-characterized breast cancer lines. We also provide interactive web-based tools to facilitate follow-on analysis of the data. Our findings show that breast cancers are diverse with respect to ligand sensitivity and signaling biochemistry. Surprisingly, triple negative breast cancers (TNBCs; which express low levels of ErbB2, progesterone and estrogen receptors) are the most broadly responsive to growth factors and HER2(amp) cancers (which overexpress ErbB2) the least. The ratio of ERK to AKT activation varies with ligand and subtype, with a systematic bias in favor of ERK in hormone receptor positive (HR(+)) cells. The factors that correlate with growth factor responsiveness depend on whether fold-change or absolute activity is considered the key biological variable, and they differ between ERK and AKT pathways. CONCLUSIONS: Responses to growth factors are highly diverse across breast cancer cell lines, even within the same subtype. A simple four-part heuristic suggests that diversity arises from variation in receptor abundance, an ERK/AKT bias that depends on ligand identity, a set of factors common to all receptors that varies in abundance or activity with cell line, and an “indirect negative regulation” by ErbB2. This analysis sets the stage for the development of a mechanistic and predictive model of growth factor signaling in diverse cancer lines. Interactive tools for looking up these results and downloading raw data are available at http://lincs.hms.harvard.edu/niepel-bmcbiol-2014/. |
format | Online Article Text |
id | pubmed-4234128 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42341282014-11-18 Analysis of growth factor signaling in genetically diverse breast cancer lines Niepel, Mario Hafner, Marc Pace, Emily A Chung, Mirra Chai, Diana H Zhou, Lili Muhlich, Jeremy L Schoeberl, Birgit Sorger, Peter K BMC Biol Research Article BACKGROUND: Soluble growth factors present in the microenvironment play a major role in tumor development, invasion, metastasis, and responsiveness to targeted therapies. While the biochemistry of growth factor-dependent signal transduction has been studied extensively in individual cell types, relatively little systematic data are available across genetically diverse cell lines. RESULTS: We describe a quantitative and comparative dataset focused on immediate-early signaling that regulates the AKT (AKT1/2/3) and ERK (MAPK1/3) pathways in a canonical panel of well-characterized breast cancer lines. We also provide interactive web-based tools to facilitate follow-on analysis of the data. Our findings show that breast cancers are diverse with respect to ligand sensitivity and signaling biochemistry. Surprisingly, triple negative breast cancers (TNBCs; which express low levels of ErbB2, progesterone and estrogen receptors) are the most broadly responsive to growth factors and HER2(amp) cancers (which overexpress ErbB2) the least. The ratio of ERK to AKT activation varies with ligand and subtype, with a systematic bias in favor of ERK in hormone receptor positive (HR(+)) cells. The factors that correlate with growth factor responsiveness depend on whether fold-change or absolute activity is considered the key biological variable, and they differ between ERK and AKT pathways. CONCLUSIONS: Responses to growth factors are highly diverse across breast cancer cell lines, even within the same subtype. A simple four-part heuristic suggests that diversity arises from variation in receptor abundance, an ERK/AKT bias that depends on ligand identity, a set of factors common to all receptors that varies in abundance or activity with cell line, and an “indirect negative regulation” by ErbB2. This analysis sets the stage for the development of a mechanistic and predictive model of growth factor signaling in diverse cancer lines. Interactive tools for looking up these results and downloading raw data are available at http://lincs.hms.harvard.edu/niepel-bmcbiol-2014/. BioMed Central 2014-03-21 /pmc/articles/PMC4234128/ /pubmed/24655548 http://dx.doi.org/10.1186/1741-7007-12-20 Text en Copyright © 2014 Niepel et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Niepel, Mario Hafner, Marc Pace, Emily A Chung, Mirra Chai, Diana H Zhou, Lili Muhlich, Jeremy L Schoeberl, Birgit Sorger, Peter K Analysis of growth factor signaling in genetically diverse breast cancer lines |
title | Analysis of growth factor signaling in genetically diverse breast cancer lines |
title_full | Analysis of growth factor signaling in genetically diverse breast cancer lines |
title_fullStr | Analysis of growth factor signaling in genetically diverse breast cancer lines |
title_full_unstemmed | Analysis of growth factor signaling in genetically diverse breast cancer lines |
title_short | Analysis of growth factor signaling in genetically diverse breast cancer lines |
title_sort | analysis of growth factor signaling in genetically diverse breast cancer lines |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234128/ https://www.ncbi.nlm.nih.gov/pubmed/24655548 http://dx.doi.org/10.1186/1741-7007-12-20 |
work_keys_str_mv | AT niepelmario analysisofgrowthfactorsignalingingeneticallydiversebreastcancerlines AT hafnermarc analysisofgrowthfactorsignalingingeneticallydiversebreastcancerlines AT paceemilya analysisofgrowthfactorsignalingingeneticallydiversebreastcancerlines AT chungmirra analysisofgrowthfactorsignalingingeneticallydiversebreastcancerlines AT chaidianah analysisofgrowthfactorsignalingingeneticallydiversebreastcancerlines AT zhoulili analysisofgrowthfactorsignalingingeneticallydiversebreastcancerlines AT muhlichjeremyl analysisofgrowthfactorsignalingingeneticallydiversebreastcancerlines AT schoeberlbirgit analysisofgrowthfactorsignalingingeneticallydiversebreastcancerlines AT sorgerpeterk analysisofgrowthfactorsignalingingeneticallydiversebreastcancerlines |